FC
RXRX icon

Financial Consulate’s Recursion Pharmaceuticals RXRX Stock Holding History

Financial Consulate’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.28K Hold
418
– – ﹤0.01% 1067
2025
Q4 		$1.71K Hold
418
– – ﹤0.01% 922
2025
Q3 		$2.04K Buy
+418
New +$2.19K ﹤0.01% 777

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Financial Consulate's RXRX Position: Q1 2026 in Review

Financial Consulate held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 418 shares worth $1.28K. The position accounts for ﹤0.01% of the portfolio, ranked #1067.

Financial Consulate first reported a position in RXRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.04K in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Financial Consulate held 418 shares of Recursion Pharmaceuticals worth $1.28K as of Q1 2026.
  • Financial Consulate left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Financial Consulate's portfolio in Q1 2026, its #1067 holding.
  • Financial Consulate first reported a position in Recursion Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Financial Consulate's Recursion Pharmaceuticals position peaked at $2.04K in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Financial Consulate's 13F filing for Q1 2026, filed 21 Apr 2026.